Valbiotis Stock
Price
Target price
€4.06
€4.06
4.370%
0.17
4.370%
-
02.05.24 / Frankfurt
WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Valbiotis
sharewise wants to provide you with the best news and tools for Valbiotis, so we directly link to the best financial data sources.
Financials
News
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis presents its 2024 financial communication calendar
Valbiotis presents its 2024 financial communication calendar
Valbiotis sets out its commercial and clinical roadmap for 2024
Valbiotis sets out its commercial and clinical roadmap for 2024
Valbiotis announces the success of its €15 M capital increase
Valbiotis announces the success of its €15 M capital increase
Valbiotis announces the launch of a capital increase
Valbiotis announces the launch of a capital increase
Valbiotis announces the availability of an amendment to the Universal Registration Document
Valbiotis announces the availability of an amendment to the Universal Registration Document
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes